Traders should monitor for the official closing announcement on or around April 27, 2026, which will confirm the delisting of FOLD shares and completion of the acquisition. Arbitrage opportunities may narrow as the closing date approaches.
Price Chart
Executive Summary
Amicus Therapeutics announced that the French Ministry of Economics and Finance has granted foreign direct investment clearance for its acquisition by BioMarin Pharmaceutical. This satisfies the final regulatory condition, with the merger now expected to close on April 27, 2026.
Key Facts
- French Ministry of Economics and Finance granted foreign direct investment (FDI) clearance for the merger with BioMarin.
- This clearance satisfies the final regulatory condition to the merger.
- The merger is expected to close on April 27, 2026.
- The transaction was first announced on December 19, 2025.
Financial Impact
The merger will result in Amicus shareholders receiving the agreed-upon consideration per share as specified in the merger agreement, though specific terms are not disclosed in this filing.
Risk Factors
- Closing is still subject to customary conditions that are to be satisfied at closing, which could delay or prevent completion.
- Regulatory or legal challenges in other jurisdictions could still emerge despite French FDI approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-016371 |
| Document: 0001140361-26-016371-index-headers.html | 0001140361-26-016371 |
| Document: 0001140361-26-016371-index.html | 0001140361-26-016371 |
| Document: 0001140361-26-016371.txt | 0001140361-26-016371 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 7, 2026 21w ago | 15-12G | — | awaiting T+1 | — | — |
Apr 27, 2026 22w ago | 8-K | $14.49 $14.49 | · 0.00% | ▲ +0.49% | — |
Apr 23, 2026 23w ago | 8-K | $14.49 $14.49 | · 0.00% | ▼ −0.16% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access